10-K: Agilon Health Reports 2024 Results: Revenue Up 40%, Focus Remains on Long-Term Growth
Annual Report
Agilon Health's 2024 annual report reveals a 40% increase in revenue alongside a net loss, as the company continues to invest in its Total Care Model and expand its network.
Summary
- Agilon Health's 2024 results show a 40% increase in total revenue, reaching $6.06 billion.
- The company experienced a net loss of $260.1 million, slightly better than the $262.8 million loss in 2023.
- Adjusted EBITDA showed a loss of $154.2 million, compared to a loss of $95.0 million in the previous year.
- The number of Medicare Advantage members served by PCPs on the platform grew by 36% to approximately 526,500.
- Medicare fee-for-service beneficiaries through ACOs increased by 48% to 132,100.
- Gross profit was $4.8 million, a decrease from $69.7 million in 2023.
- Medical margin decreased to $205.2 million from $298.7 million in the prior year.
- The company is focused on transforming healthcare by empowering primary care physicians and expanding its Total Care Model.
- Agilon Health operates through risk-bearing entities that enter into arrangements with payors for monthly payments to manage patient healthcare needs.
- The company's business model is built around its platform, long-term physician partnerships, and a growing network of physicians.
Sentiment
Score: 5
Explanation: The document presents mixed sentiment. While revenue increased, profitability metrics declined, and the company anticipates future losses. The company is taking steps to improve its internal control over financial reporting.
Positives
- Total revenue increased by 40% in 2024.
- Medicare Advantage membership grew by 36%.
- Medicare fee-for-service beneficiaries through ACOs increased by 48%.
Negatives
- The company experienced a net loss of $260.1 million in 2024.
- Adjusted EBITDA showed a loss of $154.2 million.
- Gross profit decreased to $4.8 million.
- Medical margin decreased to $205.2 million.
Risks
- The company has a history of net losses and expects expenses to increase.
- Failure to identify and develop successful new geographies, physician partners, and payors could adversely affect the company.
- Medical expenses incurred on behalf of members may exceed revenues received.
- The company relies on a limited number of key payors.
- The healthcare industry is highly competitive and fragmented.
- Security breaches, cybersecurity attacks, and loss of data could compromise sensitive information.
- The company's stock price may be volatile.
Future Outlook
The company expects to continue incurring operating losses and negative cash flows from operations for the foreseeable future due to investments in expanding its business and additional general and administrative costs.
Industry Context
The healthcare industry is highly competitive and fragmented, with increasing consolidation among physician groups and payors. Agilon Health competes with other value-based care providers, local provider networks, hospitals, and health systems.
Comparison to Industry Standards
- The document does not provide enough information to make a detailed comparison to industry standards.
- However, the document mentions that the company competes with other value-based care providers, local provider networks, hospitals, and health systems.
- The document also mentions that large, well-financed payors have in some cases developed their own managed services tools and may provide these services to their physicians and patients at discounted prices.
Legal Proceedings
- The company is subject to two class action lawsuits in federal court alleging federal securities law violations.
- The company is also subject to two putative stockholder derivative class action lawsuits.
Related Party Transactions
- The company recognized general and administrative expenses of $1.7 million to administered secondary offerings of shares of its common stock sold by CD&R.
- The company incurred expenses for provider services delivered by Population Health, LLC, which is accounted for under the equity method based on a 49% equity ownership interest held by the company.
- The company recognized revenue for technology services rendered to its CMS ACO Models investments.
- The company recognized other income for operational and administrative services provided by the company to its CMS ACO Models investments.
Stakeholder Impact
- The company's performance impacts shareholders, physician partners, payors, employees, and members.
- The company's ability to attract and retain physician partners is crucial to its success.
- The company's ability to provide high-quality care and manage healthcare costs affects member satisfaction and retention.
- The company's financial performance impacts its ability to invest in its platform and expand its network.
Next Steps
- The company will continue to improve its existing systems for operational and financial management.
- The company will continue to develop and implement appropriate activities to identify the potential occurrence of a cybersecurity event and actions necessary to address a detected cybersecurity event.
- The company will continue to develop and implement appropriate activities to maintain plans for cybersecurity resilience, remediation of the effects of a potential cybersecurity event and restoration of any capabilities that could be potentially impaired due to a cybersecurity event.
Key Dates
| Date | Description |
|---|---|
| 2016 | Agilon Health was formed. |
| 2017 | Established inaugural partnership with an anchor physician group. |
| March 2010 | Enactment of the Patient Protection and Affordable Care Act (ACA). |
| April 15, 2021 | Common stock began trading on the New York Stock Exchange (NYSE). |
| February 18, 2021 | Execution of the credit facility agreement. |
| March 1, 2021 | First Amendment to Credit Agreement. |
| April 1, 2021 | ACO REACH Model Performance Period established by CMS. |
| May 25, 2023 | Second Amendment to Credit Agreement. |
| October 31, 2023 | Completion of the disposition of MDX Hawaii, Inc. |
| December 31, 2026 | Initial term of ACO REACH entities participating medical group agreements, unless earlier terminated. |
| December 31, 2024 | End of fiscal year 2024. |
| February 21, 2025 | 412,303,066 shares of common stock outstanding. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.